Caixin Global
@caixin
Award-winning journalism from China's most respected newsroom. App:
가입 January 2010
77 팔로잉 중 91K 팬
Hong Kong’s securities regulator suspended trading in Cloudbreak Pharma after raising concerns that demand for the ophthalmic-drug developer’s IPO may have been artificially inflated.
더 보기
